Celgene

In the early days people come to Celgene because they believed that they can make a difference. The company was passionate about finding new therapies for patients who needed them, had already shown some success, and we believe that we could also build a great story, great company in Europe. We felt that a smaller entrepreneurial company that really believed in putting the patient first could differentiate itself. 2008 was a landmark year for Celgene in Europe. That year we opened our administrative facilities, our headquarters in Boudry, Switzerland. Since that time we have grown our manufacturing capabilities here and today we manufacture all our orally used products here in Switzerland to be used all over the world. One of the things that I believe differentiates us from many other organisations is the pharmaceutical industry on average invests 15% of its revenue back into research and development. At Celgene, we do more than twice that amount. Currently we have six products in the market in nine different indications in cancer, immuno inflammatory diseases and we have estimated that this year alone we are helping one hundred and fifty thousand patients with these diseases. What I'm most proud of what we have achieved at Celgene internally, is that we have been able to maintain the culture, the passion for the patients, the entrepreneurial spirit, the values that we originally had. It has to be disruptive technology. We're not here to make incremental change. We have to find those technologies that are gonna make a meaningful difference in the people's lives. I think our pipeline is full of promise. It's robust, diverse. We're exploiting a wide range of modalities. And then I would also describe it as highly innovative. We have very many first in class mechanisms of action that are really aimed at transforming the management of the diseases that we're interested in. One of the most important areas of research and development at Celgene is focused on understanding how the immune system relates to cancer. There's a growing appreciation here at Celgene and elsewhere that the interplay between immune cells and cancer is fundamental and the ability now to target immune based therapies to treat cancer is truly transforming the way we approach this disease. When we started working in myeloma and introduced the idea of using IMiDs to treat this really incurable disease, the life expectancy for a newly diagnosed patient was in the order of magnitude of several years. Fast forward now, these patients are living decades. And as we start to approach this disease focused on the immune system, we're starting to see hints of the C word cure for patients with multiple myeloma. In the last year alone, we had five major EMA approvals. So for the whole EMA region, in total, we're running probably, another 70 approvals in EMA and Eastern European markets throughout the years. I think the next ten years for Celgene hold a lot of excitement and a lot of challenge. We've been gifted with a broad pipeline. That gift means that we have to deliver against it And I think we will.

Transcript generated automatically.